Compare INBS & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INBS | XRTX |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 4.4M |
| IPO Year | N/A | N/A |
| Metric | INBS | XRTX |
|---|---|---|
| Price | $0.55 | $0.61 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 148.5K | 50.0K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,292,042.00 | N/A |
| Revenue This Year | $778.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 3.26 | N/A |
| 52 Week Low | $0.56 | $0.52 |
| 52 Week High | $2.75 | $1.79 |
| Indicator | INBS | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 28.68 | 46.07 |
| Support Level | $0.68 | $0.61 |
| Resistance Level | $0.73 | $0.67 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 5.41 | 22.06 |
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.